



## **Perma-Fix Medical to Present at 3rd Global Life Sciences Conference in Warsaw**

**Atlanta and Warsaw – June 9, 2015 – Perma-Fix Medical S.A. (WAR: PFM), a subsidiary of Perma-Fix Environmental Services, Inc. (NASDAQ:PESI),** and developer of a reliable, cost effective, non-uranium process to produce technetium-99 (Tc-99m), the most widely used medical isotope in the world, today announced that the management of Perma-Fix Medical will present at the upcoming 3rd Global Life Sciences Conference in Warsaw on Thursday, June 11, 2015 to be held on the trading floor of the Warsaw Stock Exchange, Warsaw, Poland. The management will discuss technology innovations, future opportunities and progress in the commercial launch of its new process to produce the Tc-99m medical isotope in both Europe and the North America.

The event brings together executives from leading global companies within the life sciences sector with European institutional investors. A recording of the presentation will be posted on Perma-Fix Medical's website following the conference: [www.medical-isotope.com](http://www.medical-isotope.com).

Warsaw, the financial capital of Central and Eastern Europe, is a major center of life science investment. On June 11, at the Global Life Sciences Conference, over 100 leading life science institutional investors, fund managers and analysts from Central and Eastern Europe will gather in Warsaw to discuss and assess new investment opportunities. They will have access there to Perma-Fix Medical's management team through a corporate presentation and small group meetings.

The organizers of this event are: WDM Capital, Wedbush Europe and the Filipex Enterprises. The conference can be accessed via a live Internet webcast on the website: <http://lscwarsaw.com>

### **About Perma-Fix Medical**

Perma-Fix Medical is a subsidiary of Perma-Fix Environmental Services, a NASDAQ listed company. It was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors.

### **Contact:**

David Waldman or Justyna Gudaszevska  
Crescendo Communications Europe Sp. z o.o.  
Email: [pfm@crescendo-ir.com](mailto:pfm@crescendo-ir.com)  
Tel: + 48 71 79 11 551